

PTO/SB/08a (08-03)

Approved for use through 07/31/2005. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	09/889,325
Filing Date	December 31, 2001
First Named Inventor	Saori KITAO
Art Unit	1642 1643
Examiner Name	C. YAEN
Attorney Docket Number	001107.00454

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
CY		US-6,335,435	01/01/2002	Shimamoto et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CY		OVERBEEK, PA et al., "Transgenic Animal Technology: A Laboratory Handbook," Factors affecting transgenic animal production, pp. 96-98 (1994)	
CY		WALL, RJ. "Transgenic Livestock: Progress and Prospects for the Future," <i>Transgenology</i> , Vol. 45, No. 1, pp. 57-68 (1996)	
CY		HOUEBINE, L., "Production of pharmaceutical proteins from transgenic animals," <i>J. Biotech.</i> Vol. 34, No. 3, pp. 269-87 (1994)	
CY		KAPPEL CA et al., "Regulating gene expression in transgenic animals," <i>Curr Opin Biotech.</i> Vol. 3, No. 5, pp. 548-53 (1992)	
CY		CAMERON ER. "Recent Advances in Transgenic Technology," <i>Mol. Biotech.</i> Vol. 7, No. 3, pp. 253-65 (1997)	
CY		NIEMAN II., "Transgenic farm animals get off the ground," <i>Transgenic Res.</i> ; Vol. 7, No. 1, pp. 73-5 (1998)	
CY		MULLINS JJ. and MULLINS, L. "Transgenesis in Nonmurine Species," <i>Hypertension</i> , Vol. 22, No. 4, pp. 630-3 (1993)	

Examiner  
SignatureDate  
Considered

1/22/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete If Known

Application Number	09/889,325
Filing Date	December 31 2001
First Named Inventor	Saori KITAO
Art Unit	1637-1643
Examiner Name	C. YAEN
Attorney Docket Number	004276.00003

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
cy		MULLINS, JJ. et al., "Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene," <i>Nature</i> , Vol. 344, No. 6266, pp. 541-4 (1990)	
cy		HAMMER, R. et al., "Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human B2m: An Animal Model of HLA-B27-Associated Human Disorders," <i>Cell</i> Vol. 63, pp. 1099-1112 (1990)	
cy		MULLINS, JJ. et al., "Expression of the DBA/2J Ren-2 gene in the adrenal gland of transgenic mice," <i>EMBO J</i> Vol. 8, No. 13, pp. 4065-4072 (1989)	
cy		TAUROG, JD. et al., "HLA-B27 in Inbred and Non-inbred Transgenic Mice," <i>J. Immunol.</i> , Vol. 141, No. 11, pp. 4020-3 (1988)	
cy		MULLINS, L and MULLINS, JJ. "Perspective Series: Molecular Medicine in Genetically Engineered Animals," <i>J. Clin. Invest.</i> , Vol. 98, No. 11, pp. S37-40 (1996)	

Examiner Signature

Chung HY


Date Considered

11/22/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	09/889,235
				Filing Date	July 13, 2001
				First Named Inventor	KITAO et al.
				Group Art Unit	TBA 1643
				Examiner Name	TBA C. Y. Chen
Sheet	1	of	1	Attorney Docket Number	004276.00003

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CY		Lindor, NM et al., "Rothmund-Thomson Syndrom in Siblings: Evidence for Acquired <i>In Vivo</i> Mosaicism", <u>Clinical Genetics</u> , 1996, 49:124-129	
CY		MIOZZO, M. et al., "Chromosomal Instability in Fibroblasts and Mesenchymal Tumors from 2 SIBS with Rothmund-Thomson Syndrome", <u>Int. J. Cancer</u> , 77, pp. 504-510 (1998)	

Examiner Signature		Date Considered	1/22/06
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT BY  
APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete If Known**

Application Number	09/889,325
Filing Date	January 19, 2000
First Named Inventor	Saori KITAO, et al.
Group Art Unit	To be assigned 1643
Examiner Name	To be assigned C.Yaen
Attorney Docket Number	004276.00003

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CY		KITAO, Saori, et al., Cloning of Two New Human Helicase Genes of the RecQ Family: Biological Significance of Multiple Species in Higher Eukaryotes, Genomics, 1998, pages 443-452, Vol. 54, No. 3, Academic Press, USA.	
CY		KITAO, Saori, et al., Discovery of Gene Responsible for Rothmund-Thomson Syndrome, Jikken Igaku (Experimental Medicine), 1999, pages 1237-1240, Vol. 17, No. 10, AGENE Research Institute, Japan.	X
CY		KITAO, Saori, et al., Mutations in RECQL4 Cause a Subset of Cases of Rothmund-Thomson Syndrome, Nature Genetics, 1999, pages 82-84, Vol. 22, No. 1, Nature America Inc., USA.	

Examiner Signature	<i>Chomphit</i>	Date Considered	1/22/06
-----------------------	-----------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.